This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CRISPR Stocks: Buy or Trade?
by Kevin Cook
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations
by Zacks Equity Research
Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.
CRISPR Therapeutics AG (CRSP) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics (CRSP) Surges: Stock Moves 6% Higher
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up
by Zacks Equity Research
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -41.30% and -99.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will CRISPR Therapeutics AG (CRSP) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.
CRISPR Therapeutics (CRSP) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bull of the Day: Vertex Pharma (VRTX)
by Kevin Cook
While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth
Chart Radar: Buy Software, Sell Banks
by Kevin Cook
If a bigger pullback is unfolding in this over-valued market, now is the time to plan your big dip buys.
Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.50% and -97.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $39.54, moving +1.49% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $44.67 in the latest trading session, marking a +0.84% move from the prior day.
What's in Store for Vertex in 2020 After a Remarkable 2019?
by Kinjel Shah
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.
Expand Your Portfolio with this First Profit Stock Screener
by Benjamin Rains
We are in the midst of the fourth quarter earnings season. This makes it a great time to use our 'First Profit' stock screener. The idea is to search for companies that recently reported their first quarterly profit...
CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $51.95 in the latest trading session, marking a -0.9% move from the prior day.
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.